CADL Stock Heads For Worst Ever Session — Stifel Expects Prostate Cancer Drug Launch To Be Pushed to Mid-2028
Wall Street weighed the impact of a delayed regulatory filing, with Canaccord stating that the delay could be due to differences between the drug used in Phase 3 trials and the version intended for commercial production.